Crossmark

Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant

Crossref DOI link: https://doi.org/10.1186/s12985-024-02604-7

Published Online: 2025-01-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Yan

Zhang, Ting

Wang, Zhirong

Xu, Xuemei
Funding

Funding for this research was provided by:

the basic scientific research business of Hebei North University (JYT2022005)

CAMS Innovation Fund for Medical Sciences (No. 2021-I2M-1-043)
License Information

Text and Data Mining valid from 2025-01-08

Version of Record valid from 2025-01-08
More Information

Article History

Received: 28 April 2024

Accepted: 9 December 2024

First Online: 8 January 2025

Change Date: 15 April 2026

Change Type: Update

Change Details: The original online version of this article was revised: A new reference (Reference 73) has been included and cited in the second paragraph of the Introduction section.

Declarations

:

: This study was approved by the Ethical Committee of Hebei North University (Approval No. HBNU20231222116).

: All authors approved the publication of this manuscript.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below